Skip to content

The clinical efficacy study of acupuncture intervention in the acute phase of Bell's palsy: Based on a registry study

The Clinical Efficacy Study of Acupuncture in the Acute Phase of Bell's Palsy and the Construction of a Prognostic Prediction Model: Based on a Registry Study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026001417
Enrollment
Unknown
Registered
2026-06-05
Start date
2026-07-01
Completion date
Unknown
Last updated
2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bell's palsy

Interventions

Acute phase acupuncture group:Acupuncture + routine treatment for the acute phase
Electroacupuncture + routine treatment for the recovery phase.
Acute phase non-acupuncture group:Only routine treatment for the acute phase

Sponsors

Hospital of Chengdu University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Age = 18 years old; 2. Duration of illness = 7 days (House-Brackmann grading II-VI); 3. Conscious and oriented, able to express their own opinions accurately, and willing to cooperate with the treatment; 4. Voluntarily participate in this study and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Hunt syndrome, or secondary facial paralysis caused by trauma, tumors, or otitis media; 2. Cases presenting solely with primary or secondary facial muscle spasms; 3. Cases accompanied by primary or secondary trigeminal neuralgia; 4. Patients with impaired consciousness or unstable condition; 5. Patients with severe primary diseases of the cardiovascular, liver, kidney, lung, or hematopoietic systems that are not effectively controlled; 6. Patients in the gestational or puerperal period; 7. Patients with a history of fainting, facial skin allergies, or infections; 8. Patients who have recently taken central muscle relaxant drugs or undergone nerve or motor point block therapy with botulinum toxin, alcohol, etc.; 9. Patients currently participating in other clinical studies.

Design outcomes

Primary

MeasureTime frame
Time to recovery;

Secondary

MeasureTime frame
Sunnybrook Rating;Facial Disability Index Scale;Incidence of sequelae;Treatment-related adverse events;Treatment Adherence;

Countries

China

Contacts

Public ContactGuilin Zhang

Hospital of Chengdu University of Traditional Chinese Medicine

zhanggl1997@163.com13281123561

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Jun 29, 2026